A Study to Assess the Efficacy and Safety of Golimumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis
| 対象疾患 | Colitis, Ulcerative |
|---|---|
| 相 | 第3相 |
| スポンサー | Janssen Research & Development, LLC |
| ステータス | 実施中（募集終了） |
| 参加者数 | 84 名 |
| 介入（薬剤） | Golimumab, Infliximab |
| 開始日 | 2018年10月29日 |
| 完了日 | 2023年11月21日 |
| 結果公開日 | 2025年11月14日 |
概要
The purpose of this study is to evaluate efficacy of golimumab in inducing clinical remission as assessed by the Mayo score, in pediatric participants with moderately to severely active ulcerative colitis (UC). In addition, the safety profile of golimumab, in pediatric participants with moderately to severely active UC will be assessed.
Percentage of Participants With Clinical Remission at Week 6 as Assessed by the Mayo Score
| Group 1: Golimumab | 31.9 Percentage of participants |
|---|
BENITIONS で見る ClinicalTrials.gov の原文を見る
同じ疾患の他の治験
- A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Coliti — Janssen Research & Development, LLC
- GI Permeability Change in Response to Aquamin® — James Varani
- A Study to Evaluate the Efficacy and Safety of PF-06480605 in Adults With Moderate to Seve — Hoffmann-La Roche
- A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerativ — Janssen Research & Development, LLC
- Efficacy and Mechanism of Fecal Microbiota Transplantation of the Bai Ethnicity in the Tre — First Affiliated Hospital of Kunming Medical University
- ENhanced Recovery in CHildren Undergoing Surgery — Northwestern University